ASH 2024 Summary: Full or Reduced Dose Apixaban or Rivaroxaban for E…

2024 ASH Annual Meeting Insights Hub

J. Schaefer

ASH 2024 Summary: Highlights in Bone Marrow Failure Disorders

2024 ASH Annual Meeting Insights Hub

P. Scheinberg

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Thrombosis in Patients With ITP

Platelet Disorder Support Association (PDSA)

H. Liebman

Pulmonary Embolism: Role of Catheter-Based Interventions

Baylor College of Medicine

P. Loyalka

Updates in Thrombosis and Anticoagulation

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

D. Garcia

Thalassemia: Overview of Pathophysiology and Risk for Malignancies

Ali Taher

Current Treatment Guidelines for ITP: Individualized Therapy and Eme…

Irina Murakhovskaya

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

ASH 2024 Review: New Therapies in ITP

Cleveland Clinic Taussig Cancer Institute

A. Hubben

Diagnosis of ITP (Including Differential Diagnosis) and Disease Mana…

Drew Provan

2024 Updates on Myeloproliferative Neoplasms, PV, and ET

Integrity CE

A. Tefferi

Thrombophilia Screening: Best Practices and Who Should Be Tested

COR2ED The Heart of Medical Education

S. Middeldorp, J. Connors

Is There a Role for Splenectomy in ITP?

Platelet Disorder Support Association (PDSA)

C. Kessler

Management of Treatment-Naive ITP Patients

Weill Cornell Medicine Oncology & Hematology

J. Bussel

Thrombocytopenia: Understanding Mechanisms and Inherited Forms

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

S. Panch

Misinformation in ITP

Platelet Disorder Support Association (PDSA)

D. Nugent

Anemia and Thrombocytopenia Basics

UNC Lineberger Comprehensive Cancer Center

N. Vogler